Loblaw, a prominent grocery retailer based in Brampton, Ontario, reported an increase in profits for the second quarter, driven by strong performance in its discount chains No Frills and Maxi. The company highlighted robust sales growth in its pharmacy unit, attributing this success to the popularity of generic GLP-1 weight loss medications.
During the three months ending June 20, Loblaw disclosed that its revenue surpassed $15.3 billion, marking a four percent uptick from the previous quarter. The company also saw a five percent rise in profit available to common shareholders, reaching $751 million.
In terms of same-store sales, Loblaw noted a 1.6 percent increase in its core retail food business, while its drug retail unit, which includes Shoppers Drug Mart, experienced a 4.6 percent growth. The pharmacy and health-care services segment within the drug retail unit drove this growth with a 7.5 percent increase.
Richard Dufresne, the Chief Financial Officer, emphasized the positive impact of generic GLP-1 drugs on pharmacy performance. He mentioned that lower generic drug prices were being offset by higher volumes, leading to expectations of increased revenue, gross profit dollars, and margin rates.
GLP-1 drug sales surged by 40 percent year-to-date, as noted by Loblaw executives, reflecting a trend observed in the previous quarter. CEO Per Bank highlighted a shift in consumer behavior towards purchasing more frozen vegetables over fresh produce due to inflation, particularly citing a substantial rise in fresh tomato prices.
Despite food price inflation, Loblaw’s No Frills and Maxi stores are positioned to cater to value-seeking customers. Dufresne underscored the company’s success in hard discount markets and conventional retail, outperforming industry peers. He mentioned that Loblaw’s internal food inflation metric remained lower than Canada’s grocery Consumer Price Index (CPI).
Statistics Canada reported a decline in the inflation rate to 2.8 percent in June, with grocery price hikes moderating to 3.9 percent from 4.3 percent in May. Loblaw’s stock on the Toronto exchange remained relatively stable on Thursday, with a year-to-date gain of approximately six percent.